Ovid Therapeutics Inc. Debt Securities, Available-for-sale, Amortized Cost
Ovid Therapeutics Inc. (OVID) had Debt Securities, Available-for-sale, Amortized Cost of $158.89 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $158.89M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $71.65M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $77.31M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $4.99M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $158.89M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $71.65M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $77.31M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $4.99M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $9.94M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $21.86M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $26.77M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $47.66M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $47.29M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $59.51M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $78.79M 10-K · filed 2025-03-11 | $78.79M 10-K · filed 2024-03-08 |
| 2023-09-30 | $29.64M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $24.89M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $54.66M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $84.18M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $79.68M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $79.64M 10-Q · filed 2022-08-09 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-13 | |
| 2020-03-31 | $30.93M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $34.84M 10-K · filed 2021-03-15 | |
| 2019-03-31 | $5.04M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $5.01M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $22.00M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $40.08M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $44.99M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |